{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:09:57Z","timestamp":1783901397643,"version":"3.55.0"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Herein synchronous occurrence of Hodgkin lymphoma and secondary myelodysplastic syndrome in a 60 year old male patient with small cell lung cancer treated with combined chemotherapy (carboplatin and paclitaxel) and radiotherapy is presented. The objective of this report is to stress the importance of documenting and monitoring adverse drug reactions that arise from chemotherapy.<\/jats:p>\n                  <jats:p>After four years of treatment with the combined chemotherapy, the patient presented inguinal lymphadenopathy and enlarged lymph nodes and histopathology rapport was suggestive for plasmacytoid variant of Castleman disease. Three years later, biopsy of lymph node was performed and diagnosis of Hodgkin lymphoma \u2013 mixed cellularity has been established. Molecular analyses revealed presence of dominant monoclonal population of the immunoglobulin genes in the oligo\/monoclonal background. Bone marrow biopsy findings suggested secondary myelodysplasia and revealed signs of hematopoietic cells dismaturation with signs of megaloblastic maturation of the erytropoetic lineage, appearance of ALIP (abnormal localization of immature precursors) in the myeloid lineage and dysplastic megakaryocytes. In addition, an increased level of polyclonal plasmacytes (lambda vs kappa was 60%:40%) was found.<\/jats:p>\n                  <jats:p>Hodgkin lymphoma and MDS occurring after 4 years of carboplatin\/paclitaxel therapy might be contributed to the accumulation of alkylator-related DNA damage. This emphasize the need of outlining a monitoring plan regarding development of secondary leukemia and other malignant hematological proliferations should be outlined in the protocols.<\/jats:p>","DOI":"10.2478\/prilozi-2018-0010","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T18:17:53Z","timestamp":1524075473000},"page":"97-103","source":"Crossref","is-referenced-by-count":1,"title":["Secondary Hodgkin Lymphoma and Myelodysplastic Syndrome (MDS) After Paclitaxel-Carboplatin Treatment in a Patient with Small Cell Lung Cancer"],"prefix":"10.2478","volume":"38","author":[{"given":"Marija","family":"Petrusevska","sequence":"first","affiliation":[{"name":"Institute of preclinical and clinical pharmacology and toxicology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d Skopje , Republic of Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina Panovska","family":"Stavridis","sequence":"additional","affiliation":[{"name":"University Clinic of hematology, University \u201cSs. Cyril and Methodius\u201d Skopje , Republic of Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Mladenovska","sequence":"additional","affiliation":[{"name":"Department of clinical pharmacy, Faculty of Pharmacy , University \u201cSs. Cyril and Methodius\u201d Skopje , Republic of Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Petrushevska","sequence":"additional","affiliation":[{"name":"Institute of pathology, Faculty of Medicine , University \u201cSs. Cyril and Methodius\u201d Skopje , Republic of Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,4,16]]},"reference":[{"key":"2026071212052264459_j_prilozi-2018-0010_ref_001_w2aab3b7c10b1b6b1ab1b1b1Aa","doi-asserted-by":"crossref","unstructured":"1. Karim SM, Zekri J. Chemotherapy for small cell lung cancer: a comprehensive review. Oncol Rev 2012;6:16-36.10.4081\/oncol.2012.e4","DOI":"10.4081\/oncol.2012.e4"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_002_w2aab3b7c10b1b6b1ab1b1b2Aa","doi-asserted-by":"crossref","unstructured":"2. Yeasmin S, Nakayama K, Ishibashi M, Oride A, Katagiri A, Purwana IN, Iida K, Nakayama N, Ishikura H, Miyazaki K. Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel- and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review. Int J Gynecol Cancer 2008;18(6):1371-6.10.1111\/j.1525-1438.2007.01185.x18217963","DOI":"10.1111\/j.1525-1438.2007.01185.x"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_003_w2aab3b7c10b1b6b1ab1b1b3Aa","doi-asserted-by":"crossref","unstructured":"3. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur J Cancer 2008;44:1507-15.10.1016\/j.ejca.2008.04.01818571399","DOI":"10.1016\/j.ejca.2008.04.018"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_004_w2aab3b7c10b1b6b1ab1b1b4Aa","doi-asserted-by":"crossref","unstructured":"4. Koklu H, Tufan A, Erkul Y, Akyurek N, Civelek R. Secondary acute myeloid leukemia arising early after cyclophosphamide treatment. Int J Clin Pharm 2015;37(2):289-91.10.1007\/s11096-015-0069-425612567","DOI":"10.1007\/s11096-015-0069-4"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_005_w2aab3b7c10b1b6b1ab1b1b5Aa","doi-asserted-by":"crossref","unstructured":"5. See HT, Thomas DA, Bueso-Ramos C, Kavanagh J. Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer. Int J Gynecol Cancer 2006;16:236-40.10.1111\/j.1525-1438.2006.00491.x16515597","DOI":"10.1136\/ijgc-00009577-200602001-00038"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_006_w2aab3b7c10b1b6b1ab1b1b6Aa","doi-asserted-by":"crossref","unstructured":"6. Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol. 2013; 40(6):10-2410.1053\/j.seminoncol.2013.09.013386774324331189","DOI":"10.1053\/j.seminoncol.2013.09.013"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_007_w2aab3b7c10b1b6b1ab1b1b7Aa","doi-asserted-by":"crossref","unstructured":"7. Gajendra A, Sharma A, Sharma R, Gupta SK, Sood N, Sachdev R. Hodkin Lymphoma in a case of chronic myeloid leukemia treated with tyrosine kinase inhibitors. Turk Patoloji Derg 2017; (ahead of print).10.5146\/tjpath.2016.0136828272671","DOI":"10.5146\/tjpath.2016.01368"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_008_w2aab3b7c10b1b6b1ab1b1b8Aa","doi-asserted-by":"crossref","unstructured":"8. Lucy A. Godley, Richard A. Larson. Therapy-related Myeloid Leukemia. Semin Oncol 2008;35(4):418\u201329.10.1053\/j.seminoncol.2008.04.012260044518692692","DOI":"10.1053\/j.seminoncol.2008.04.012"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_009_w2aab3b7c10b1b6b1ab1b1b9Aa","doi-asserted-by":"crossref","unstructured":"9. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin\u2019s lymphoma patients. J Clin Oncol 2003;21(5):897-906.10.1200\/JCO.2003.07.11312610191","DOI":"10.1200\/JCO.2003.07.113"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_010_w2aab3b7c10b1b6b1ab1b1c10Aa","doi-asserted-by":"crossref","unstructured":"10. Pinheiro RF, Chauffaille ML. Myelodysplastic syndrome secondary to chemotherapy or radiotherapy - treatment-related MDS. Rev Bras Hematol Hemoter 2006;28(3):201-3.10.1590\/S1516-84842006000300010","DOI":"10.1590\/S1516-84842006000300010"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_011_w2aab3b7c10b1b6b1ab1b1c11Aa","doi-asserted-by":"crossref","unstructured":"11. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008;22: 240\u2013810.1038\/sj.leu.240507818200041","DOI":"10.1038\/sj.leu.2405078"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_012_w2aab3b7c10b1b6b1ab1b1c12Aa","doi-asserted-by":"crossref","unstructured":"12. Seymour JF, Juneja SK, Campbell LJ, Ellims PH, Estey EH, Prince HM. Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Leukemia 1999;13(11):1735-40.10.1038\/sj.leu.240155210557046","DOI":"10.1038\/sj.leu.2401552"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_013_w2aab3b7c10b1b6b1ab1b1c13Aa","doi-asserted-by":"crossref","unstructured":"13. Tasaka T, Matsuhashi Y, Uehara E, Tamura T, Kakazu N, Abe T, Nagai M. Secondary acute monocytic leukemia with a translocation t(8;16) (p11;p13): case report and review of the literature. Leuk Lymphoma 2004;45(3):621-5.10.1080\/1042819031000159305815160929","DOI":"10.1080\/10428190310001593058"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_014_w2aab3b7c10b1b6b1ab1b1c14Aa","unstructured":"14. Ishikawa M, Nakayama K, Rahman MT, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Iida K, Nakayama N, Miyazaki K. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following chemotherapy (paclitaxel and carboplatin) and radiation therapy in ovarian cancer: a case report. Eur J Gynaec Oncol 2014;35(4):443-8."},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_015_w2aab3b7c10b1b6b1ab1b1c15Aa","doi-asserted-by":"crossref","unstructured":"15. Takagi H, Ichigo S, Matsunami K, Takagi H, Ikeda T, Murase T, Imai A. Occurrence of myelodysplastic syndrome during paclitaxel and carboplatin-based chemotherapy for recurrent ovarian cancer: Case report. Open J Obst Gynec 3:232-4.10.4236\/ojog.2013.32043","DOI":"10.4236\/ojog.2013.32043"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_016_w2aab3b7c10b1b6b1ab1b1c16Aa","doi-asserted-by":"crossref","unstructured":"16. Noronha V, Berliner N, Ballen KK, Lacy J, Kracher J, Baehring J, Henson JW. Treatment-related my elodysplasia\/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature. Neuro-oncol 2006;8(3):280\u20133.10.1215\/15228517-2006-003187195016728498","DOI":"10.1215\/15228517-2006-003"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_017_w2aab3b7c10b1b6b1ab1b1c17Aa","doi-asserted-by":"crossref","unstructured":"17. Kumar CC. Genetic Abnormalities and Challenges in the Treatment of Acute Myeloid Leukemia. Genes Cancer 2011;2(2):95\u2013107.10.1177\/1947601911408076311124521779483","DOI":"10.1177\/1947601911408076"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_018_w2aab3b7c10b1b6b1ab1b1c18Aa","doi-asserted-by":"crossref","unstructured":"18. Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin\u2019s disease: a report from the German Hodgkin\u2019s lymphoma study group. J Clin Oncol 2003;21(18):3440-6.10.1200\/JCO.2003.07.16012668650","DOI":"10.1200\/JCO.2003.07.160"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_019_w2aab3b7c10b1b6b1ab1b1c19Aa","doi-asserted-by":"crossref","unstructured":"19. Ng AK, Patricia Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002;100:1989-96.10.1182\/blood-2002-02-063412200357","DOI":"10.1182\/blood-2002-02-0634"},{"key":"2026071212052264459_j_prilozi-2018-0010_ref_020_w2aab3b7c10b1b6b1ab1b1c20Aa","doi-asserted-by":"crossref","unstructured":"20. Groen HJ, Fokkema E, Biesma B, Kwa B, van Putten JW, Postmus PE, Smit EF. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol 1999;17(3):927-32.10.1200\/JCO.1999.17.3.92710071286","DOI":"10.1200\/JCO.1999.17.3.927"}],"container-title":["PRILOZI"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/prilozi\/38\/3\/article-p97.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/prilozi-2018-0010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:50:14Z","timestamp":1783900214000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/prilozi-2018-0010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,4,16]]},"published-print":{"date-parts":[[2017,12,1]]}},"alternative-id":["10.2478\/prilozi-2018-0010"],"URL":"https:\/\/doi.org\/10.2478\/prilozi-2018-0010","relation":{},"ISSN":["1857-8985","1857-9345"],"issn-type":[{"value":"1857-8985","type":"electronic"},{"value":"1857-9345","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12,1]]}}}